LRRK2 and Parkinson disease: Indeed, transgenic mice with LRRK2 G2019S mutation, which increases the kinase activity of the protein by about threefold, exhibited increased gliosis and neuroinflammation under PD-related conditions [22,23,24], while LRRK2 KO rodents displayed mitigated neuroinflammatory effects upon different inflammatory challenges [13,25,26].